Who
Shefali Agarwal
Director
Company insider
Files Form 4 as: Director, Fate Therapeutics; Director, Gritstone bio; Chief Medical Officer, Epizyme.
In numbers
- Trades disclosed
- 65
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $293K
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 23 Jul 2018
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 12 Jun 2026filed 15 Jun 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —87,900 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —51,800 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —51,800 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —38,000 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —937 at $0.00 | filing |
| 4 Apr 2025filed 8 Apr 2025 | Gritstone biooption or derivative | SEC FORM 4 Code J | —19,000 at $0.00 | filing |
| 17 Jun 2024filed 20 Jun 2024 | Gritstone biooption or derivative | SEC FORM 4 Code A | —51,800 at $0.00 | filing |
| 7 Jun 2024filed 11 Jun 2024 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 Jun 2023filed 21 Jun 2023 | Gritstone biooption or derivative | SEC FORM 4 Code A | —51,800 at $0.00 | filing |
| 6 Jun 2023filed 7 Jun 2023 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Epizyme | SEC FORM 4 Code D | —179,247 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Epizyme | SEC FORM 4 Code D | —107,292 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizymeoption or derivative | SEC FORM 4 Code M | —56,527 at $0.00 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizymeoption or derivative | SEC FORM 4 Code M | —43,473 at $0.00 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizymeoption or derivative | SEC FORM 4 Code M | —400,000 at $0.00 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizyme | SEC FORM 4 Code M | $79K56,527 at $1.39 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizyme | SEC FORM 4 Code M | $60K43,473 at $1.39 | filing |
| 9 Aug 2022filed 11 Aug 2022 | Epizyme | SEC FORM 4 Code M | $556K400,000 at $1.39 | filing |
News
Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Shefali Agarwal; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.